GlassScriptPhysician profile
Sheldon C Berger
NPI 1114982089
$13,914.78
in general payments reported to CMS, 2019-2025
41 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,001 · 2020: $1,777 · 2021: $2,274 · 2022: $2,274 · 2023: $1,887 · 2024: $2,579 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,573 · Education: $14.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,573.36 |
| Education | $14.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,879.98 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,667.80 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Gilead Sciences, INC. | $1,522.99 | 2019-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,233.34 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,049.87 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $678.50 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $410.23 | 2019-2023 | Clenpiq, Rebyota, Cimzia |
| Qol Medical, LLC | $334.26 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $314.29 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $304.19 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $263.37 | 2019-2025 | Linzess |
| Lilly USA, LLC | $199.44 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $197.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $181.43 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $136.44 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.